ClinicalTrials.gg

Program

imetelstat

Also written as “Imetelstat Sodium (GRN163L)”, “Imetelstat” and “Imetelstat sodium”.

Its studies are mostly in Primary Myelofibrosis · Multiple Myeloma · Myelodysplastic Syndromes · Carcinoma, Non-Small-Cell Lung · Thrombocythemia, Essential, led by 2 companies.

Furthest: phase 4, since Nov 3, 202616 company-led studies, 4 open or runningNext primary completion: Feb 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Geron154 open or runningphase 4since Nov 3, 2026Jul 25, 2005Feb 2027phase 1 · NCT05371964
GCP-Service International West10 open or runningphase 2since Oct 13, 2022Oct 13, 2022none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 1 study since Jul 25, 2005.

  1. Apr 4, 2006Phase 1 study in RecurrenceGeron · NCT00310895 · 85 enrolled · United States
  2. Jul 31, 2007Phase 1 study in Lung NeoplasmsGeron · NCT00510445 · 27 enrolled · United States
  3. Jan 3, 2008Phase 1 study in Multiple MyelomaGeron · NCT00594126 · 20 enrolled · United States
  4. Jul 16, 2008Phase 1 study in Multiple MyelomaGeron · NCT00718601 · 40 enrolled · United States
  5. Aug 7, 2008Phase 1 study in Breast NeoplasmsGeron · NCT00732056 · 24 enrolled · United States
  6. Jun 3, 2010Phase 2 study in Carcinoma, Non-Small-Cell LungGeron · NCT01137968 · 116 enrolled · United States, Canada, Germany
  7. Nov 11, 20102 phase 2 studiesGeron · NCT01243073, NCT01242930
  8. Nov 18, 2012Phase 2 study in Primary MyelofibrosisGeron · NCT01731951 · 80 enrolled · United States
  9. Apr 21, 2015Phase 2 study in Primary MyelofibrosisGeron · NCT02426086 · 107 enrolled · United States, Belgium, Canada and more
  10. Oct 27, 2015Phase 3 study in Myelodysplastic SyndromesGeron · NCT02598661 · 289 enrolled · United States, Belgium, Canada and more
  11. Sep 18, 2020Phase 3 study in Primary MyelofibrosisGeron · NCT04576156 · 327 enrolled · United States, Argentina, Australia and more
  12. May 5, 2022Phase 1 study in Primary MyelofibrosisGeron · NCT05371964 · 30 enrolled · United States
  13. Oct 13, 2022GCP-Service International West's first study: phase 2 study in Myelodysplastic SyndromesNew to GCP-Service International WestGCP-Service International West · NCT05583552 · 46 enrolled · Australia, France, Germany
  14. Nov 3, 2026Phase 4 study in Anemia, Refractory, with Excess of BlastsGeron · NCT07939451 · 100 planned

Ahead

  1. Feb 2027Primary completion: phase 1 study in Primary MyelofibrosisGeron · NCT05371964
  2. Jun 30, 2028Primary completion: phase 3 study in Primary MyelofibrosisGeron · NCT04576156
  3. Jul 2030Primary completion: phase 4 study in Anemia, Refractory, with Excess of BlastsGeron · NCT07939451

TargetBeta

TERT →read by rule
“Telomerase reverse transcriptase inhibitor”ChEMBL 37, by rule

Other programs on TERT

ProgramCompanyFurthest phaseStudies
Anti-TERT/Anti-CD3 T-cell Engager CBX-663rulecrossbow-therapeutics-incphase 11

Studies

All 16 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07939451Anemia, Refractory, with Excess of Blasts4Not yet recruitingGeronJul 2030100
NCT05583552Myelodysplastic Syndromes · Australia, France, Germany2CompletedGCP-Service International WestMar 27, 202546
NCT05371964Primary Myelofibrosis · United States1Active, not recruitingGeronFeb 202730
NCT04576156Primary Myelofibrosis · United States, Argentina, Australia and more3Active, not recruitingGeronJun 30, 2028327
NCT02598661Myelodysplastic Syndromes · United States, Belgium, Canada and more3Active, not recruitingGeronOct 13, 2023289
NCT02426086Primary Myelofibrosis · United States, Belgium, Canada and more2CompletedGeronApr 26, 2018107
NCT01731951Primary Myelofibrosis · United States2CompletedGeronMay 24, 201880
NCT01242930Multiple Myeloma · United States2CompletedGeronNov 201413
NCT01243073Thrombocythemia, Essential · United States, Germany, Switzerland2CompletedGeronOct 201320
NCT01137968Carcinoma, Non-Small-Cell Lung · United States, Canada, Germany2CompletedGeronSep 2013116
NCT00732056Breast Neoplasms · United States1CompletedGeronSep 201124
NCT00718601Multiple Myeloma · United States1CompletedGeronOct 201140
NCT00594126Multiple Myeloma · United States1CompletedGeronJul 201120
NCT00510445Lung Neoplasms · United States1CompletedGeronApr 201127
NCT00310895Recurrence · United States1CompletedGeronMar 201385
NCT00124189Leukemia, Lymphocytic, Chronic, B-Cell · United States1CompletedGeronMar 201348

How it is read

Names in the registry

  • “Imetelstat Sodium (GRN163L)”, 4 entries
  • “Imetelstat”, 3 entries
  • “Imetelstat sodium”, 2 entries
  • “GRN163L”, 2 entries
  • “Imetelstat (3.55 mg/kg)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.